<?xml version="1.0"?><rss version="2.0"><channel><title>antibody - Latest News</title><link>http://news.prlog.org/tag/antibody/</link><description>antibody - Latest News (Press Releases) - Read news before it's news</description><language>en-us</language><ttl>3600</ttl>
<item><title>'New technologies to capture over 10% of the antibody therapeutics market by 2023' shows Visiongain</title><link>http://www.prlog.org/12083466-new-technologies-to-capture-over-10-of-the-antibody-therapeutics-market-by-2023-shows-visiongain.html</link><description>A new report by Visiongain shows that next-generation technologies will become a major driver for the antibody therapeutics market.</description></item>
<item><title>Peter Senter, Ph.D., to Deliver Opening Keynote at Cancer Biologics 2013</title><link>http://www.prlog.org/12040350-peter-senter-phd-to-deliver-opening-keynote-at-cancer-biologics-2013.html</link><description>CHI’s 4th Annual Cancer Biologics, February 13-15, 2013, San Francisco, CA</description></item>
<item><title>Sedia Biosciences Receives NIAID SBIR Grant for New Avidity Assay to Determine HIV-1 Incidence</title><link>http://www.prlog.org/11929095-sedia-biosciences-receives-niaid-sbir-grant-for-new-avidity-assay-to-determine-hiv-1-incidence.html</link><description>Phase I funding of the competitive grant is to develop a novel commercial assay to measure host HIV antibody avidity (&quot;binding ability&quot;), an indicator of antibody maturation, which can be used to determine recent vs. long-term HIV-1 infections.</description></item>
<item><title>tebu-bio is now Certified Service Provider for RayBiotech’s portfolio of antibody arrays</title><link>http://www.prlog.org/11922822-tebu-bio-is-now-certified-service-provider-for-raybiotechs-portfolio-of-antibody-arrays.html</link><description>tebu-bio is proud to announce that they have been awarded the designation of Certified Service Provider (CSP) of RayBiotech’s antibody array testing services.</description></item>
<item><title>CRI-report: Research Report on Chinese Monoclonal Antibody Industry, 2012</title><link>http://www.prlog.org/11817748-cri-report-research-report-on-chinese-monoclonal-antibody-industry-2012.html</link><description>Monoclonal antibody still belongs to high-end products in Chinese market, mainly depending on imports.</description></item>
<item><title>CHI Releases Conference Proceedings CD from PepTalk 2012 - The Protein Science Week</title><link>http://www.prlog.org/11806885-chi-releases-conference-proceedings-cd-from-peptalk-2012-the-protein-science-week.html</link><description>Those that missed last month's event can get a CD with 80 speaker presentations from 4 pipelines: formulation, purification, biotherapeutics, and expression. Individual track CDs and the overall event CD is available at CHI-PepTalk.com.</description></item>
<item><title>New Data on Mentrik Biotech’s Ocaratuzumab (AME-133v) Published in Clinical Cancer Research</title><link>http://www.prlog.org/11796209-new-data-on-mentrik-biotechs-ocaratuzumab-ame-133v-published-in-clinical-cancer-research.html</link><description>New pre-clinical and clinical data on Mentrik Biotech’s ocaratuzumab, a humanized, next-generation anti-CD20 monoclonal antibody for treatment of follicular lymphoma, was released in Clinical Cancer Research, published by the AACR.</description></item>
<item><title>Allergan and CMO at Altheos to speak at Ocular Drug Discovery conference Feb 27-28, 2012 Las Vegas</title><link>http://www.prlog.org/11760902-allergan-and-cmo-at-altheos-to-speak-at-ocular-drug-discovery-conference-feb-27-28-2012-las-vegas.html</link><description>David Woodward, Senior Director of Biological Sciences at Allergan and Barbara Wirostko, Chief Medical Officer at Altheos will give a joint featured presentation at the 4th Ocular Diseases and Drug Discovery Conference</description></item>
<item><title>'World revenues for monoclonal antibody therapies will reach $62.3bn in 2015' predicts Visiongain</title><link>http://www.prlog.org/11666473-world-revenues-for-monoclonal-antibody-therapies-will-reach-623bn-in-2015-predicts-visiongain.html</link><description>A new report by Visiongain predicts that overall revenues for monoclonal antibody (mAb) therapies will rise between 2011 and 2021. The world mAb drugs market will reach $62.3bn in 2015, up from revenues of $44.6bn (USD) in 2010.</description></item>
<item><title>Insight Pharma Report Announces Engineering Next-Generation Therapeutic Proteins Report</title><link>http://www.prlog.org/11611730-insight-pharma-report-announces-engineering-next-generation-therapeutic-proteins-report.html</link><description>Engineering Next-Generation Therapeutic Proteins: Trends and Markets To 2020 Report</description></item>
<item><title>AbboMax announces the availability of new Mouse anti-Desmoglein 3 (Dsg3) Monoclonal Antibody</title><link>http://www.prlog.org/11608669-abbomax-announces-the-availability-of-new-mouse-anti-desmoglein-3-dsg3-monoclonal-antibody.html</link><description>Desmogleins are members of the desmosomal cadherins that provide adhesive integrity to desmosomes between adjoining keratinocytes. Desmoglein 3 is autoantigen of the autoimmune disease pemphigus vulgaris, and plays role in squamous cell cancer.</description></item>
<item><title>AnaSpec Introduces Speedy 28-day Custom Polyclonal Antibody Service</title><link>http://www.prlog.org/11510199-anaspec-introduces-speedy-28-day-custom-polyclonal-antibody-service.html</link><description>Leveraging proven technology from Eurogentec, AnaSpec's parent company, this protocol uses a proprietary mixture of Freund's free immuno-stimulatory compounds.</description></item>
<item><title>Anti-5-Methylcytidine Antibody - Most Cited</title><link>http://www.prlog.org/11138958-anti-5-methylcytidine-antibody-most-cited.html</link><description>AnaSpec, Eurogentec Group is pleased to offer anti-5-methylcytidine (Clone 33D3), Eurogentec’s most popular monoclonal antibody, for use in epigenetics research.</description></item>
<item><title>RayBiotech Renews Biomarker Discovery Grant Program for 2011</title><link>http://www.prlog.org/11120464-raybiotech-renews-biomarker-discovery-grant-program-for-2011.html</link><description>RayBiotech, Inc., announced today it will renew its Biomarker Discovery Pilot Grant program for 2011 and will accept applications for restricted pilot grants of $5,000 to $20,000 worth of RayBiotech products and/or services beginning in early 2011.</description></item>
<item><title>tebu-bio announces the launch of their fourth Mini-website</title><link>http://www.prlog.org/11083985-tebu-bio-announces-the-launch-of-their-fourth-mini-website.html</link><description>Since the launch of their first mini-website dedicated to SilenciX, tebu-bio has subsequently released sites focussed on Preadipocytes and Antibody Arrays, with the most recent addition now centered around CryostaX™.</description></item>
<item><title>OBodies attracts top talent for new therapeutic and diagnostic innovations</title><link>http://www.prlog.org/11071593-obodies-attracts-top-talent-for-new-therapeutic-and-diagnostic-innovations.html</link><description>Therapeutic protein and antibody engineering expert Dr. Mark Liddament appointed Research Manager at OBodies</description></item>
<item><title>Overview of Landscape of Antibody Technology Companies Available through Bharatbook</title><link>http://www.prlog.org/11056196-overview-of-landscape-of-antibody-technology-companies-available-through-bharatbook.html</link><description>Bharatbook added a new report on &quot;Antibody Technology Companies 2010&quot; into its market report catalogue for reselling.</description></item>
<item><title>Global Monoclonal Antibody Market Analysis new report added to ReportBuyer.com</title><link>http://www.prlog.org/11041819-global-monoclonal-antibody-market-analysis-new-report-added-to-reportbuyercom.html</link><description>According to our new research report 'Global Monoclonal Antibody Market Analysis', the global monoclonal antibodies market witnessed an annual growth rate of around 13% during 2008-2009.</description></item>
<item><title>Global Information Inc. is pleased to announce a new IBC Asia Conference</title><link>http://www.prlog.org/11016472-global-information-inc-is-pleased-to-announce-new-ibc-asia-conference.html</link><description>IBC USA - Antibody Engineering - Register today</description></item>
<item><title>OctoChem Inc. Announces A New Distribution Model For The Life Science Manufacturer</title><link>http://www.prlog.org/11015423-octochem-inc-announces-new-distribution-model-for-the-life-science-manufacturer.html</link><description>OctoChem Inc. has announced a new services solution that gives the Life Sciences manufacturer the alternative distribution channel it needs with the complete control and visibility it deserves.</description></item>
<item><title>RayBiotech Awarded NIH/STTR Grant for Endometriosis Research</title><link>http://www.prlog.org/11014021-raybiotech-awarded-nihsttr-grant-for-endometriosis-research.html</link><description>RayBiotech, Inc., a leading developer and supplier of multiplex protein and antibody arrays, was recently awarded an STTR research grant to identify protein markers that could potentially be used in a diagnostic test for endometriosis.</description></item>
<item><title>Highly specific monoclonal antibodies available from Randox Life Sciences</title><link>http://www.prlog.org/10821635-highly-specific-monoclonal-antibodies-available-from-randox-life-sciences.html</link><description>Randox Life Sciences is a recognised primary manufacturer of high quality, cost effective monoclonal antibodies to both classic and novel targets.</description></item>
<item><title>RayBiotech Announces Biomarker Grant Awardees</title><link>http://www.prlog.org/10663929-raybiotech-announces-biomarker-grant-awardees.html</link><description>RayBiotech announced the recipients of its Biomarker Discovery Grants. By sponsoring these awards, RayBiotech intends to demonstrate that any researcher with a modest research budget can discover disease-related biomarkers using its antibody arrays.</description></item>
<item><title>New Market Report: Preclinical Development of Monoclonal Antibodies and Related Biologicals</title><link>http://www.prlog.org/10652426-new-market-report-preclinical-development-of-monoclonal-antibodies-and-related-biologicals.html</link><description>Recently published research from Business Insights, &quot;Preclinical Development of Monoclonal Antibodies and Related Biologicals: Emerging technologies and new therapeutic candidates&quot;, is now available at Fast Market Research</description></item>
<item><title>Cyto 360 Launched New Protocol For Custom Antibody Production That Can be Finished in Four Weeks</title><link>http://www.prlog.org/10612500-cyto-360-launched-new-protocol-for-custom-antibody-production-that-can-be-finished-in-four-weeks.html</link><description>Generally custom antibody development takes more time for process but with the launch of new four phase protocol it can be possible to produce antibodies in just four weeks and is capable of managing 500-1000 BALB/c mice and nude mice.</description></item>
<item><title>Novus Biologicals launches first TMEM97 antibody on the market</title><link>http://www.prlog.org/10589696-novus-biologicals-launches-first-tmem97-antibody-on-the-market.html</link><description>Novus Biologicals, an international supplier of antibodies, biological products and materials to various scientific sectors, announce that they have launched the first TMEM97 antibody onto the market.</description></item>
<item><title>Isogenica announces new partnership with UK Ministry of Defence agency</title><link>http://www.prlog.org/10532832-isogenica-announces-new-partnership-with-uk-ministry-of-defence-agency.html</link><description>Isogenica and the Defence Science and Technology Laboratory develop antimicrobial peptide drugs with potential to treat MRSA</description></item>
<item><title>Novus Biologicals Enhances Stem Cell Product Offering</title><link>http://www.prlog.org/10516829-novus-biologicals-enhances-stem-cell-product-offering.html</link><description>Novus Biologicals, an international supplier of antibodies, biological products and materials to various scientific sectors</description></item>
<item><title>Novus Biologicals Launches New Histone Antibodies For DNA Repair Research</title><link>http://www.prlog.org/10515563-novus-biologicals-launches-new-histone-antibodies-for-dna-repair-research.html</link><description>Novus Biologicals, an international supplier of antibodies, biological products and materials to various scientific sectors, have launched new Histone antibodies for use in DNA repair research.</description></item>
<item><title>Cambridge-based biotech Isogenica announces new partnership with Phylogica</title><link>http://www.prlog.org/10515116-cambridgebased-biotech-isogenica-announces-new-partnership-with-phylogica.html</link><description>Isogenica and Phylogica target peptide drugs for inflammatory disease</description></item>
<item><title>Novus Biologicals Launches New HIF Prolyl Hydroxylase Antibody</title><link>http://www.prlog.org/10514782-novus-biologicals-launches-new-hif-prolyl-hydroxylase-antibody.html</link><description>Novus Biologicals, an international supplier of antibodies, biological products and materials to various scientific sectors, have launched a new HIF Prolyl Hydroxylase antibody for use in research</description></item>
<item><title>Role of YAP in Cancer Revealed Using EGFR Phosphorylation Array</title><link>http://www.prlog.org/10507490-role-of-yap-in-cancer-revealed-using-egfr-phosphorylation-array.html</link><description>A study in the December issue of Nature Cell Biology identified a potential drug target for breast cancer. RayBiotech Antibody Arrays were vital to this discovery, including one detecting phosphorylation of EGFR family receptors at multiple sites.</description></item>
<item><title>Novus Biologicals Announce The Opening Of Their New, Upgraded Validation Facility</title><link>http://www.prlog.org/10474214-novus-biologicals-announce-the-opening-of-their-new-upgraded-validation-facility.html</link><description>Cambridge, England - Novus Biologicals, an international supplier of antibodies, biological products and materials to various scientific sectors, have announced the opening of a new validation facility at their headquarters.</description></item>
<item><title>Novus Biologicals announces opening of European office</title><link>http://www.prlog.org/10404515-novus-biologicals-announces-opening-of-european-office.html</link><description>Novus Biologicals, an international supplier of antibodies, biological products and materials to various scientific sectors, is proud to announce the opening of their first European office in Cambridge, England.</description></item>
<item><title>RayBiotech to Award Biomarker Discovery Grants</title><link>http://www.prlog.org/10353160-raybiotech-to-award-biomarker-discovery-grants.html</link><description>RayBiotech today announced the establishment of its Biomarker Discovery Pilot Grant program, consisting of restricted grants of $10,000 to $20,000 worth of RayBiotech products and services for protein biomarker discovery.</description></item>
<item><title>Visiongain: Monoclonal Antibodies in Cancer Therapy 2009-2024 on reports-research.com</title><link>http://www.prlog.org/10324960-visiongain-monoclonal-antibodies-in-cancer-therapy-20092024-on-reportsresearchcom.html</link><description>Monoclonal antibody-based therapies for cancer are a thriving part of the biotechnology sector, as our new market report explains.</description></item>
<item><title>GenScript to Attend 1st Annual International Congress of Antibodies</title><link>http://www.prlog.org/10242910-genscript-to-attend-1st-annual-international-congress-of-antibodies.html</link><description>GenScript will sponsor the BIT Life Sciences’ 1st Annual International Congress of Antibodies (ICA). CEO Dr. Frank Zhang will give keynote speech to share thoughts on antibody drug development.</description></item>
<item><title>GenScript Offers Free Bio-reagent Sample Bundles</title><link>http://www.prlog.org/10232306-genscript-offers-free-bioreagent-sample-bundles.html</link><description>GenScript offers high quality bundled bio-reagent samples to appreciate customers and assist in biology research under current tough economic condition.</description></item>
<item><title>GenScript antibody service guarantees ELISA titer of 1:20000 and positive Western blot results</title><link>http://www.prlog.org/10129753-genscript-antibody-service-guarantees-elisa-titer-of-120000-and-positive-western-blot-results.html</link><description>GenScript raises the quality standard for its antibody packages.</description></item>
<item><title>Conference on Recombinant Antibodies</title><link>http://www.prlog.org/10127510-conference-on-recombinant-antibodies.html</link><description>Conference to be held at 22nd - 23rd January 2009, BSG Conference Centre, London, UK</description></item>
<item><title>IRI To Launch MunoTM Boost - Immune System Booster</title><link>http://www.prlog.org/10076121-iri-to-launch-munotm-boost-immune-system-booster.html</link><description>IRI Separation Technologies (TSX.V:IRI) is the manufacturer of a remarkable new dietary supplement that enhances the human body’s natural immune system through direct supplementation of actual antibodies.</description></item>
<item><title>Lee Biosolutions Human Salivary Amylase production increased to meet worldwide demand</title><link>http://www.prlog.org/10037921-lee-biosolutions-human-salivary-amylase-production-increased-to-meet-worldwide-demand.html</link><description>Lee Biosolutions’ extensive human donor program allows them to process over 500 liters of human saliva per year for their human salivary amylase production requirements for IVD manufacturers and clinical researchers.</description></item>
<item><title>High Purity Human Ferritin Antigen and Polyclonal Antibodies from Lee Biosolutions</title><link>http://www.prlog.org/10037919-high-purity-human-ferritin-antigen-and-polyclonal-antibodies-from-lee-biosolutions.html</link><description>Lee Biosolutions, Inc. announces the increased production and availability of the highest purity affinity purified polyclonal Ferritin antibodies and native human ferritin antigens to the clinical research community and IVD manufacturers.</description></item></channel></rss>